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in specific aetiologies of chronic liver diseases. However, there is
mounting evidence that SSI should be considered as an accurate
and promising elastography technique in the field of chronic liver
diseases.
To conclude, we are living in an era of great and frequent tech-
nological innovations, which is particularly exciting, but we have
the duty to analyse, criticize and finally validate as quick as pos-
sible each new progress in order to ultimately provide the best
diagnosis and treatment for all patients.
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JOURNAL OF HEPATOLOGYAlbumin infusion in cirrhotic patients with infections other than
spontaneous bacterial peritonitis: End of the story?To the Editor:
We read with interest the recent manuscript by Thevenot et al.
[1] which adds data to the debate on the potential beneficial
effect of albumin administration during episodes of infections
other than spontaneous bacterial peritonitis (SBP) in cirrhotic
patients [2–4].Reply to: ‘‘New imaging assisted methods for liver
fibrosis quantification: Is it really favorable to classical
transient elastography?’’Non-invasive assessment of liver fibrosis with impulse
elastography: Comparison of Supersonic Shear Imaging with
ARFI and FibroScan.
To the Editor:
We read with great interest comments by Dr. Lanthier et al. [1]
regarding our article published in Journal of Hepatology [2]. We
thank the authors for their kind interest in our work and
welcome the opportunity to clarify points they raised.
First, in our studywe did not apply nor evenmention reliability
criteria regarding the Supersonic Shear Imaging (SSI) technique. As
Dr. Lanthier said, SSI is quite a recent technique, and to date, no
study has focused on the description or definition of reliability cri-
teria for this technique. In our study, interquartile range (IQR)/liver
stiffness measurement (LSM) was <0.10 in 207 patients (69%),
between 0.10 and 0.30 in 91 (30%), and >0.30 in 3 patients (1%).
So, it is quite obvious that the reliability criteria of FibroScan
are probably not applicable to SSI, but we believe that the defini-
tion of such criteria requires a large multicentre study and should
not be performed too hastily in a single centre study.
Second, we’d like to clarify the key point that the failure rate of
FibroScan in our study is low, around 2.6%, because the XL probe
was used for obese patients (i.e. with body mass index P30 kg/
m2) (30% of patients of our study). In our experience, the failure
rate of SSI is very close to that of the M probe of FibroScan.
Indeed, we can notice that the failure rate of SSI in our study
(10.4% in the whole population; 28% for obese patients but only
2.6% for others) is close to the failure rate of theM probe described
in the study by de Lédinghen et al. [3] among a patient population
quite representative of our study population although with a
slightly lower BMI (8.4% in the whole population; 26% for obese
patients but only 2.5% for others). Unfortunately, as for ARFI and
FibroScan, the reliability of liver stiffness measurement with
SSI is dependant on the quality of the shear wave transmission,
which rapidly decreases as weight increases. This is likely to be
evident in SSI and ARFI techniques where operators can notice
the strong relationship between the reliability of the LSM and
the quality of the spatial resolution on the B-mode US image.
Finally, as we’ve discussed, we agree that further studies are
needed assessing the diagnostic performances and limits of SSIJournal of Hepatology 2015 vol. 63 j 763–773 767
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other than SBP, were randomly assigned to receive albumin infu-
sion or no treatment in addition to antibiotics. The primary out-
comes were renal failure and mortality rates. The study failed to
show any beneficial effect on these outcomes, although albumin
infusion delayed the onset of renal failure. However, in our opin-
ion, some bias could have influenced the results. First, the preva-
lence of ascites was significantly higher in the patients
randomized to albumin and antibiotics than in the patients
assuming antibiotics alone (75.8 vs. 59.6%; p = 0.017). The
development of infection and the consequent increase in vasodi-
latation may have influenced the rate of renal failure and progno-
sis of the former group differently from the control group inwhich
the number of patients with ascites was lower. Second, the suc-
cess or failure of antibiotic therapies were not analyzed and, as
we know, the course of infections is a further important parame-
ter for the prognosis of cirrhotic patients [5,6]. Third, as also dis-
cussed by the authors, many violations occurred in the protocol
and 17 patients in the control group also received albumin for
large volume paracentesis during the first week.
Thus, in our opinion, the results of the present study should
not discourage further investigations in cirrhotic patients with
infections also considering the wide range of potential benefits
of albumin administration in this setting (antioxidant function,
immunomodulation, anti-inflammatory activity and transport of
many endogenous and exogenous substances), in addition to its
well-known effect as plasma expander [7]. Among these
additional properties, in particular, the effect of the albumin
infusion during the therapy with moderately/highly protein-
bound antibiotics should also be evaluated, considering the
relevant role of hypoalbuminemia on the pharmacokinetics of
these antibiotics [8].
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Letters to the EditorReply to ‘‘Albumin infusion in cirrhotic patients with
non-SBP infections: End of the story?’’
To the Editor:
We greatly appreciate the comments by Lucidi et al. [1]. Firstly,
we acknowledge that, despite well-conducted randomization to
reduce the risk of selection bias at trial entry [2], the presence
of ascites was more frequently reported in the albumin (ALB)
group as compared with the control group (75.8 vs. 59.6;
p = 0.017). We have to remember that using an alpha risk of 5%,
the probability of there being no imbalance between groups for
any one baseline characteristic is 0.95. Assuming the characteris-
tics are independent, there is a non-negligible 1  (0.95)n proba-
bility of observing a significant imbalance between groups when
comparing n baseline characteristics. For instance, in Table 1
showing the baseline characteristics of patients [2], there were
at least 10 independent variables meaning that the chance of at
least one statistically significant imbalance was 0.40. In order
to improve the precision of the treatment effect estimate, and
to avoid any confounding, the two Cox multivariate analyses per-
formed to determine predictive variables associated with renal
failure and death at 3 months were adjusted for ascites, which
was no longer significant.
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